U.S. Markets closed

Dr. Reddy's Laboratories Limited (RDY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
38.22-0.85 (-2.18%)
At close: 4:02PM EDT

38.22 -0.01 (-0.03%)
After hours: 4:02PM EDT

People also watch
HDBWITIBNTTMINFY

Dr. Reddy's Laboratories Limited

8-2-337, Road No. 3
Banjara Hills
Hyderabad 500034
India
91 40 4900 2900
http://www.drreddys.com

SectorHealthcare
IndustryDrug Manufacturers - Other
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Mr. Gunupati Venkateswara Prasad B.Sc. (Chem. Eng.), M.S. (Indl. Admn.)Co-Chairman, Chief Exec. Officer, Managing Director and Member of the Management Council1.86MN/A57
Mr. Kallam Satish Reddy B.Tech., M.S.Chairman and Member of the Management Council1.37MN/A50
Mr. Saumen Chakraborty B.Sc. (H), MBA-IIMPres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt CouncilN/AN/A56
Dr. Sripada ChandrasekharPres, Global Head of HR and Member of Management CouncilN/AN/A60
Mr. Abhijit Mukherjee B.Tech. (Chem.)Chief Operating Officer and Member of the Management CouncilN/AN/A59
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients (APIs) and intermediates, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations and new chemical entities (NCEs) for dermatology and neurology therapeutic areas. It also engages in the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as metabolic disorders, and pain and inflammation; and has a portfolio of in-licensed patented dermatology products. As of March 31, 2016, this segment had 19 active products in development programs pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. It has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreements with Merck Serono and Amgen. Dr. Reddy’s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Corporate Governance

Dr. Reddy's Laboratories Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.